{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:51:22Z","timestamp":1791294682906,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s00059-024-05285-8","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T12:29:20Z","timestamp":1732624160000},"page":"17-24","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Erh\u00f6hter Blutdruck und Bluthochdruck","Elevated blood pressure and hypertension"],"prefix":"10.1007","volume":"50","author":[{"given":"Raphael S.","family":"Schmieder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heribert","family":"Schunkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"issue":"14","key":"5285_CR1","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa2206916","volume":"389","author":"C Magnussen","year":"2023","unstructured":"Magnussen\u00a0C et\u00a0al (2023) Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality. N\u00a0Engl J Med 389(14):1273\u20131285","journal-title":"N Engl J Med"},{"issue":"10285","key":"5285_CR2","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","volume":"397","author":"Blood Pressure Lowering Treatment Trialists Collaboration","year":"2021","unstructured":"Blood Pressure Lowering Treatment Trialists Collaboration (2021) Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet 397(10285):1625\u20131636","journal-title":"Lancet"},{"issue":"10022","key":"5285_CR3","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad\u00a0D et\u00a0al (2016) Blood pressure lowering for prevention of cardiovascular disease and death: a\u00a0systematic review and meta-analysis. Lancet 387(10022):957\u2013967","journal-title":"Lancet"},{"issue":"10258","key":"5285_CR4","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","volume":"396","author":"GBD 2019 Risk Factors Collaborators","year":"2020","unstructured":"GBD 2019 Risk Factors Collaborators (2020) Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: a\u00a0systematic analysis for the Global Burden of Disease Study 2019. Lancet 396(10258):1223\u20131249","journal-title":"Lancet"},{"issue":"25","key":"5285_CR5","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","volume":"82","author":"GA Mensah","year":"2023","unstructured":"Mensah\u00a0GA et\u00a0al (2023) Global Burden of Cardiovascular Diseases and Risks, 1990\u20132022. J\u00a0Am Coll Cardiol 82(25):2350\u20132473","journal-title":"J Am Coll Cardiol"},{"issue":"38","key":"5285_CR6","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy\u00a0JW et\u00a0al (2024) 2024 ESC Guidelines for the management of elevated blood pressure and hypertension: Developed by the task force on the management of elevated blood pressure and hypertension of the European Society of Cardiology (ESC) and endorsed by the European Society of Endocrinology (ESE) and the European Stroke Organisation (ESO). Eur Heart\u00a0J 45(38):3912\u20134018","journal-title":"Eur Heart J"},{"issue":"12","key":"5285_CR7","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia\u00a0G et\u00a0al (2023) 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J\u00a0Hypertens 41(12):1874\u20132071","journal-title":"J Hypertens"},{"key":"5285_CR8","volume-title":"Nationale VersorgungsLeitlinie Hypertonie \u2013 Langfassung, Version\u00a01.0. 2023","author":"Bundes\u00e4rztekammer (B\u00c4K)","year":"2023","unstructured":"Bundes\u00e4rztekammer (B\u00c4K), Kassen\u00e4rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) (2023) Nationale VersorgungsLeitlinie Hypertonie \u2013 Langfassung, Version\u00a01.0. 2023"},{"issue":"10305","key":"5285_CR9","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S0140-6736(21)01921-8","volume":"398","author":"Blood Pressure Lowering Treatment Trialists Collaboration","year":"2021","unstructured":"Blood Pressure Lowering Treatment Trialists Collaboration (2021) Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet 398(10305):1053\u20131064","journal-title":"Lancet"},{"issue":"6","key":"5285_CR10","doi-asserted-by":"publisher","first-page":"e1003599","DOI":"10.1371\/journal.pmed.1003599","volume":"18","author":"AC Pinho-Gomes","year":"2021","unstructured":"Pinho-Gomes\u00a0AC et\u00a0al (2021) Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: An individual participant data meta-analysis. PLoS Med 18(6):e1003599","journal-title":"PLoS Med"},{"issue":"11","key":"5285_CR11","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1161\/HYPERTENSIONAHA.123.21496","volume":"80","author":"Z Bidel","year":"2023","unstructured":"Bidel\u00a0Z et\u00a0al (2023) Sex-Specific Effects of Blood Pressure Lowering Pharmacotherapy for the Prevention of Cardiovascular Disease: An Individual Participant-Level Data Meta-Analysis. Hypertension 80(11):2293\u20132302","journal-title":"Hypertension"},{"issue":"9","key":"5285_CR12","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S2213-8587(22)00172-3","volume":"10","author":"M Nazarzadeh","year":"2022","unstructured":"Nazarzadeh\u00a0M et\u00a0al (2022) Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type\u00a02 diabetes: an individual participant-level data meta-analysis. Lancet Diabetes Endocrinol 10(9):645\u2013654","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"5285_CR13","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1161\/01.HYP.0000094221.86888.AE","volume":"42","author":"JE Neter","year":"2003","unstructured":"Neter\u00a0JE et\u00a0al (2003) Influence of weight reduction on blood pressure: a\u00a0meta-analysis of randomized controlled trials. Hypertension 42(5):878\u2013884","journal-title":"Hypertension"},{"issue":"11","key":"5285_CR14","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding\u00a0JPH et\u00a0al (2021) Once-Weekly Semaglutide in Adults with Overweight or Obesity. N\u00a0Engl J Med 384(11):989\u20131002","journal-title":"N Engl J Med"},{"issue":"4","key":"5285_CR15","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1161\/HYPERTENSIONAHA.115.06853","volume":"67","author":"HC Gay","year":"2016","unstructured":"Gay\u00a0HC et\u00a0al (2016) Effects of Different Dietary Interventions on Blood Pressure: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Hypertension 67(4):733\u2013739","journal-title":"Hypertension"},{"issue":"1","key":"5285_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/eurjpc\/zwaa141","volume":"29","author":"H Hanssen","year":"2022","unstructured":"Hanssen\u00a0H et\u00a0al (2022) Personalized exercise prescription in the prevention and treatment of arterial hypertension: a\u00a0Consensus Document from the European Association of Preventive Cardiology (EAPC) and the ESC Council on Hypertension. Eur J Prev Cardiol 29(1):205\u2013215","journal-title":"Eur J Prev Cardiol"},{"issue":"10347","key":"5285_CR17","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0140-6736(22)00847-9","volume":"400","author":"GBD 2020 Alcohol Collaborators","year":"2022","unstructured":"GBD 2020 Alcohol Collaborators (2022) Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a\u00a0systematic analysis for the Global Burden of Disease Study 2020. Lancet 400(10347):185\u2013235","journal-title":"Lancet"},{"issue":"14","key":"5285_CR18","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMoa2111437","volume":"385","author":"W Zhang","year":"2021","unstructured":"Zhang\u00a0W et\u00a0al (2021) Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. N\u00a0Engl J Med 385(14):1268\u20131279","journal-title":"N Engl J Med"},{"issue":"20","key":"5285_CR19","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1901281","volume":"384","author":"CE Lewis","year":"2021","unstructured":"Lewis\u00a0CE et\u00a0al (2021) Final Report of a\u00a0Trial of Intensive versus Standard Blood-Pressure Control. N\u00a0Engl J Med 384(20):1921\u20131930","journal-title":"N Engl J Med"},{"issue":"5","key":"5285_CR20","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1001\/jamacardio.2019.6192","volume":"5","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan\u00a0M et\u00a0al (2020) Assessment of Long-term Benefit of Intensive Blood Pressure Control on Residual Life Span: Secondary Analysis of the Systolic Blood Pressure Intervention Trial (SPRINT). JAMA Cardiol 5(5):576\u2013581","journal-title":"JAMA Cardiol"},{"issue":"3","key":"5285_CR21","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1161\/HYPERTENSIONAHA.113.02089","volume":"63","author":"G Reboldi","year":"2014","unstructured":"Reboldi\u00a0G et\u00a0al (2014) Tight versus standard blood pressure control in patients with hypertension with and without cardiovascular disease. Hypertension 63(3):475\u2013482","journal-title":"Hypertension"},{"issue":"4","key":"5285_CR22","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1001\/jama.2019.21402","volume":"323","author":"JW McEvoy","year":"2020","unstructured":"McEvoy\u00a0JW et\u00a0al (2020) Association of Isolated Diastolic Hypertension as Defined by the 2017 ACC\/AHA Blood Pressure Guideline With Incident Cardiovascular Outcomes. JAMA 323(4):329\u2013338","journal-title":"JAMA"},{"issue":"21","key":"5285_CR23","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1093\/eurheartj\/ehab111","volume":"42","author":"AP Jacobsen","year":"2021","unstructured":"Jacobsen\u00a0AP et\u00a0al (2021) A\u00a0cohort study and meta-analysis of isolated diastolic hypertension: searching for a\u00a0threshold to guide treatment. Eur Heart\u00a0J 42(21):2119\u20132129","journal-title":"Eur Heart J"},{"issue":"5","key":"5285_CR24","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1161\/HYPERTENSIONAHA.121.17766","volume":"78","author":"JW McEvoy","year":"2021","unstructured":"McEvoy\u00a0JW et\u00a0al (2021) Isolated Diastolic Hypertension in the IDACO Study: An Age-Stratified Analysis Using 24-Hour Ambulatory Blood Pressure Measurements. Hypertension 78(5):1222\u20131231","journal-title":"Hypertension"},{"issue":"10305","key":"5285_CR25","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/S0140-6736(21)01922-X","volume":"398","author":"CK Chow","year":"2021","unstructured":"Chow\u00a0CK et\u00a0al (2021) Initial treatment with a\u00a0single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a\u00a0phase\u00a03, randomised, double-blind, active-controlled trial. Lancet 398(10305):1043\u20131052","journal-title":"Lancet"},{"issue":"10305","key":"5285_CR26","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/S0140-6736(21)01964-4","volume":"398","author":"T Kahan","year":"2021","unstructured":"Kahan\u00a0T (2021) Low-dose combination of blood pressure-lowering medicines. Lancet 398(10305):1022\u20131023","journal-title":"Lancet"},{"issue":"1","key":"5285_CR27","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/HYP.0000000000000203","volume":"79","author":"NK Choudhry","year":"2022","unstructured":"Choudhry\u00a0NK et\u00a0al (2022) Medication Adherence and Blood Pressure Control: A\u00a0Scientific Statement From the American Heart Association. Hypertension 79(1):e1\u2013e14","journal-title":"Hypertension"},{"issue":"6","key":"5285_CR28","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1097\/HJH.0000000000002398","volume":"38","author":"AJ Lawson","year":"2020","unstructured":"Lawson\u00a0AJ et\u00a0al (2020) Nonadherence to antihypertensive medications is related to pill burden in apparent treatment-resistant hypertensive individuals. J\u00a0Hypertens 38(6):1165\u20131173","journal-title":"J Hypertens"},{"issue":"2","key":"5285_CR29","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1161\/HYPERTENSIONAHA.120.15781","volume":"77","author":"G Parati","year":"2021","unstructured":"Parati\u00a0G et\u00a0al (2021) Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension: A\u00a0Systematic Review and Meta-Analysis. Hypertension 77(2):692\u2013705","journal-title":"Hypertension"},{"issue":"7404","key":"5285_CR30","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","volume":"326","author":"MR Law","year":"2003","unstructured":"Law\u00a0MR et\u00a0al (2003) Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 326(7404):1427","journal-title":"BMJ"},{"issue":"30","key":"5285_CR31","doi-asserted-by":"publisher","first-page":"e4071","DOI":"10.1097\/MD.0000000000004071","volume":"95","author":"MA Paz","year":"2016","unstructured":"Paz\u00a0MA et\u00a0al (2016) Treatment efficacy of anti-hypertensive drugs in monotherapy or combination: ATOM systematic review and meta-analysis of randomized clinical trials according to PRISMA statement. Medicine 95(30):e4071","journal-title":"Medicine"},{"issue":"5","key":"5285_CR32","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","volume":"72","author":"RM Carey","year":"2018","unstructured":"Carey\u00a0RM et\u00a0al (2018) Resistant Hypertension: Detection, Evaluation, and Management: A\u00a0Scientific Statement From the American Heart Association. Hypertension 72(5):e53\u2013e90","journal-title":"Hypertension"},{"issue":"10008","key":"5285_CR33","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams\u00a0B et\u00a0al (2015) Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a\u00a0randomised, double-blind, crossover trial. Lancet 386(10008):2059\u20132068","journal-title":"Lancet"},{"issue":"2","key":"5285_CR34","first-page":"Cd008996","volume":"2","author":"TS Tam","year":"2017","unstructured":"Tam\u00a0TS et\u00a0al (2017) Eplerenone for hypertension. Cochrane Database Syst Rev 2(2):Cd8996","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"5285_CR35","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1161\/HYPERTENSIONAHA.111.00633","volume":"61","author":"GF DiBona","year":"2013","unstructured":"DiBona\u00a0GF (2013) Sympathetic nervous system and hypertension. Hypertension 61(3):556\u2013560","journal-title":"Hypertension"},{"issue":"15","key":"5285_CR36","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1093\/eurheartj\/ehad054","volume":"44","author":"E Barbato","year":"2023","unstructured":"Barbato\u00a0E et\u00a0al (2023) Renal denervation in the management of hypertension in adults. A\u00a0clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart\u00a0J 44(15):1313\u20131330","journal-title":"Eur Heart J"},{"issue":"10","key":"5285_CR37","first-page":"Cd002252","volume":"10","author":"E Abalos","year":"2018","unstructured":"Abalos\u00a0E et\u00a0al (2018) Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 10(10):Cd2252","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"5285_CR38","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1056\/NEJMoa1404595","volume":"372","author":"LA Magee","year":"2015","unstructured":"Magee\u00a0LA et\u00a0al (2015) Less-tight versus tight control of hypertension in pregnancy. N\u00a0Engl J Med 372(5):407\u2013417","journal-title":"N Engl J Med"},{"issue":"6","key":"5285_CR39","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1093\/ehjcvp\/pvz082","volume":"6","author":"R C\u00edfkov\u00e1","year":"2020","unstructured":"C\u00edfkov\u00e1\u00a0R et\u00a0al (2020) Peripartum management of hypertension: a\u00a0position paper of the ESC Council on Hypertension and the European Society of Hypertension. Eur Heart J Cardiovasc Pharmacother 6(6):384\u2013393","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"5285_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/ijgo.13763","volume":"154 Suppl 1","author":"LC Poon","year":"2021","unstructured":"Poon\u00a0LC et\u00a0al (2021) A\u00a0literature review and best practice advice for second and third trimester risk stratification, monitoring, and management of pre-eclampsia: Compiled by the Pregnancy and Non-Communicable Diseases Committee of FIGO (the International Federation of Gynecology and Obstetrics). Int J Gynaecol Obstet 154 Suppl 1(1):3\u201331","journal-title":"Int J Gynaecol Obstet"},{"key":"5285_CR41","unstructured":"Guideline of the German Society of Gynecology and Obstetrics (S2k -Level), A.R.N., . Hypertensive Disorders in Pregnancy: Diagnosis and Therapy"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-024-05285-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-024-05285-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-024-05285-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T18:47:04Z","timestamp":1738003624000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00059-024-05285-8"}},"subtitle":["ESC-Leitlinie 2024 r\u00fcckt Risikoreduktion in den Fokus","Focus of the 2024 ESC guidelines on risk reduction"],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["5285"],"URL":"https:\/\/doi.org\/10.1007\/s00059-024-05285-8","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"assertion":[{"value":"18 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"R.S. Schmieder deklariert Forschungsbeziehungen mit einer For-Profit-Organisation (ReCor: Sponsoring des GPS-Registers am DHM) und mit Not-for-Profit-Organisationen (Bayerisches Gesundheitsministerium, Deutsche Herzallianz und Dr. Rolf M. Schwiete Stiftung: Sponsoring der VRONI-Studie). H. Schunkert gibt Honorare f\u00fcr Beratungs\u2011\/Rednert\u00e4tigkeiten f\u00fcr folgende Firmen an: Amarin, Amgen, AstraZeneca, Bayer Vital GmbH, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Medtronic, MSD Sharp & Dohme, Novartis, Pharmacosmos, Sanofi-Aventis, Servier, Synlab.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}